NCT02003898CompletedNot Applicable
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Medtronic Diabetes
- Enrollment
- 372
- Locations
- 43
- Primary Endpoint
- Mean Change in A1C From Baseline to 1 Year
Study Overview
Brief Summary
The purpose of this study is to evaluate the Threshold Suspend (TS) feature of the Medtronic MiniMed® 530G insulin pump in patients 16 and older with insulin requiring diabetes.
Detailed Description
Multi-center trial is initiated to observe the Threshold Suspend (TS) feature with a sensor-augmented insulin pump (Medtronic MiniMed® 530G insulin pump) in patients 16 and older with insulin requiring diabetes over a period of one year.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 16 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subject is age 16 or older at time of screening
- •Subject has been diagnosed with diabetes mellitus for at least one year prior to screening.
- •Subject is currently on pump therapy.
- •Subject is transitioning to the 530G insulin pump system with the TS feature turned ON.
- •Subject is willing to complete all study related activities
- •Subject is willing to upload data every 21 days from the study pump
- •Subject must have Internet access and access to a computer system that meets the requirements for uploading the pumps. This may include use of family or friend's computer system with Internet access.
- •Subject is able (by insurance or financial means) to cover the initial investment and ongoing cost of the 530G insulin pump and consumables, CGM, Bayer CONTOUR Next Link RF enabled meter and supplies for the length of the study- 1 year.
Exclusion Criteria
- •Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study devices in the last 2 weeks.
- •Subject is a woman of child-bearing potential who has a positive pregnancy test at screening or plans to become pregnant during the course of the study
- •Subject is being treated for hyperthyroidism at time of screening
- •Subject has an abnormality (>1.8mg/dL) in creatinine at time of screening visit
- •Subject has an abnormality (out of reference range) in thyroid-stimulating hormone (TSH) at time of screening visit. If TSH is out of range, Free T3 and Free T4 will be tested. Subject may be included with TSH out of range as long as Free T3 and Free T4 are in normal reference range.
- •Subject has taken any oral, injectable, or IV steroids within 8 weeks from time of screening visit, or plans to take any oral, injectable, or IV steroids during the course of the study
- •Subject is currently abusing illicit drugs
- •Subject is currently abusing prescription drugs
- •Subject is currently abusing alcohol
- •Subject has sickle cell disease or hemoglobinopathy
- •Subject has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening or plans to receive red blood cell transfusion or erythropoietin over the course of study participation
- •Subject diagnosed with current eating disorder such as anorexia or bulimia
- •Subject has been diagnosed with chronic kidney disease that results in chronic anemia
- •Subject is on dialysis
Arms & Interventions
Medtronic MiniMed 530G Insulin Pump
Experimental
All subjects received diabetes treatment using the Medtronic MiniMed 530G insulin pump.
Intervention: Medtronic MiniMed 530G Insulin Pump (Device)
Outcomes
Primary Outcomes
Mean Change in A1C From Baseline to 1 Year
Time Frame: 1 year
Comparison of A1C measurement from baseline to end of study in the CEP266 study population. The overall mean change in A1C from baseline will be estimated and compared by a non-inferiority test with an A1C margin of 0.4% and a significance level of 0.025 (one-sided) with the CEP 266 study population.
Secondary Outcomes
- Mean Change in A1C From Baseline to 1 Year, Baseline A1c of 7% to 9%(1 year)
- Mean Change in A1C From Baseline to 1 Year, Baseline A1c Below 7%(1 year)
- Mean Change in A1C From Baseline to 1 Year, Baseline A1c > 9%(1 year)
Investigators
Study Sites (43)
Loading locations...
Similar Trials
Terminated
Not Applicable
Impedance Threshold Device Tilt StudyOrthostatic HypotensionNCT00137319United States Army Institute of Surgical Research2
Completed
Not Applicable
Magnetic Resonance (MR) Conditional Tachyarrhythmia Therapy Products Post-approval StudyTachyarrhythmiaNCT02849769Medtronic10,979
Terminated
Phase 2
Application of Impedance Threshold Device Technologies to Treat and Prevent Hypotension During DialysisIntradialytic HypotensionEnd Stage Renal DiseaseLow Blood PressureNCT00576524Children's Hospital of Philadelphia2
Recruiting
Not Applicable
Patient Specific Talus Spacer Post Approval StudyAvascular Necrosis of the TalusNCT05364606Paragon 2850
Unknown
Phase 3
Safety and Effectiveness of Cortical Stimulation in the Treatment of Stroke Patients With Upper Extremity HemiparesisHemiparesisStrokeNCT00170716Northstar Neuroscience174